Stocktoria
Amphastar Pharmaceuticals, Inc. AMPH
Amphastar Pharmaceuticals, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $719.9M | $732.0M | $644.4M | $499.0M | $437.8M | $349.8M | $322.4M | $294.7M | $240.2M | $255.2M |
| Gross profit | $356.1M | $373.9M | $351.1M | $248.9M | $199.7M | $143.3M | $131.9M | $107.0M | $90.5M | $104.2M |
| R&D expense | $85.8M | $73.9M | $73.7M | $74.8M | $60.9M | $67.2M | $68.9M | $57.6M | $43.5M | $41.5M |
| Operating income | $140.4M | $205.4M | $197.0M | $107.5M | $69.9M | $11.0M | -$39,000 | -$8.6M | -$1.3M | $15.4M |
| Interest expense | — | — | $27.2M | $1.8M | $885,000 | $374,000 | $119,000 | $243,000 | $826,000 | $1.0M |
| Income tax | $25.5M | $29.7M | $31.8M | $23.5M | $20.6M | $3.5M | $13.7M | -$3.3M | -$2.4M | $4.8M |
| Net income | $98.1M | $159.5M | $137.5M | $91.4M | $62.1M | $1.4M | $48.9M | -$5.7M | $3.6M | $9.8M |
| EPS (diluted) | $2.03 | $3.06 | $2.60 | $1.74 | $1.25 | $0.03 | $0.98 | $-0.12 | $0.08 | $0.21 |
| Operating cash flow | $156.1M | $213.4M | $183.5M | $89.2M | $98.0M | $57.3M | $41.8M | $38.2M | $39.2M | $38.6M |
| Free cash flow | $121.2M | $172.3M | $145.3M | $65.1M | $70.5M | $23.4M | $207,000 | -$8.6M | $4.1M | $17.2M |
| Cash & equivalents | $170.2M | $151.6M | $144.3M | $156.1M | $126.4M | $92.6M | $73.7M | $86.3M | $65.6M | $72.4M |
| Inventory | $176.9M | $153.7M | $105.8M | $103.6M | $92.8M | $96.8M | $110.5M | $69.3M | $63.6M | $79.8M |
| Total assets | $1.6B | $1.6B | $1.5B | $742.0M | $671.5M | $631.2M | $587.0M | $513.6M | $451.1M | $427.7M |
| Total liabilities | $840.5M | $845.2M | $873.5M | $213.3M | $226.0M | $182.5M | $159.4M | $149.2M | $117.3M | $98.5M |
| Shareholders' equity | $788.8M | $732.3M | $639.4M | $528.7M | $445.5M | $448.7M | $427.5M | $364.4M | $333.7M | $329.3M |
Growth · year-over-year · Revenue CAGR 12.2%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -1.7% | +13.6% | +29.1% | +14.0% | +25.1% | +8.5% | +9.4% | +22.7% | -5.9% | +1.4% |
| Net income growth | -38.5% | +16.0% | +50.5% | +47.1% | +4327.4% | -97.1% | — | -257.3% | -62.9% | — |
| EPS growth | -33.7% | +17.7% | +49.4% | +39.2% | +4066.7% | -96.9% | — | -250.0% | -61.9% | — |
| Free cash flow growth | -29.7% | +18.6% | +123.1% | -7.6% | +201.3% | +11209.7% | — | -309.7% | -76.1% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.